slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 33,481-33,510
Pages 3,950
Rows per page 30
Component
33,481-33,510 of 118,471
03
This slide serves as a critical analysis of clinical trial integrity, specifically focusing on the SONAR trial and subsequent reporting practices.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster2 hits
05
The text highlights discrepancies in reported ESKD numbers between different sources and questions the statistical significance of the primary renal outcome.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster2 hits
06
The slide uses data from the RADAR trial to challenge the validity of UACR as a reliable surrogate endpoint for kidney function.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter2 hits
08
The slide argues that the drug Atrasentan acts as a 'band-aid' by masking symptoms via surrogate endpoints without providing long-term structural benefit.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter2 hits
09
The slide uses Kaplan-Meier survival curves to illustrate the convergence of outcomes between placebo and Atrasentan groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter2 hits
10
The slide provides a critical analysis of a standard medical metric, highlighting its inaccuracies and limitations in clinical practice.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter2 hits
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter2 hits
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter2 hits
16
The slide highlights discrepancies in reported clinical trial data, specifically regarding ESKD progression and adverse event reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 2 hits
27
The slide uses a table of clinical trial results to illustrate a methodological critique of composite endpoints.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 2 hits
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction2 hits
30
The slide uses a combination of text-based argument and visual data (charts) to expose potential manipulation of clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction2 hits
03
This slide functions as a forensic accounting critique, highlighting specific instances of alleged financial misreporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The MonsterLoop · The Reveal2 hits
05
The slide uses forensic accounting analysis to challenge the legitimacy of reported revenue and the operational substance of the SanReno joint venture.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · The Reveal2 hits
07
The slide details specific accounting irregularities regarding warrant valuation and cost reimbursements, supported by extensive footnotes referencing SEC filings.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Loop · The Reveal2 hits
13
The slide uses a screenshot of a third-party listing platform as evidence of potential portfolio vacancy, contrasting it with company-reported metrics.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg2 hits
14
Includes footnotes 16-19 detailing calculation methodology and site visit observations.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg2 hits
17
The slide presents property-specific due diligence findings regarding rent24's occupancy.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle2 hits
24
Includes a photograph of a building directory as evidence of tenant occupancy; references footnotes 44 and 45.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle2 hits
25
The slide uses a table to provide context for a forensic argument about asset inflation. Footnotes 46-48 provide specific source citations for the claims.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory2 hits
34
The slide highlights a discrepancy between reported valuation stability and the reliance on internal assessments.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory2 hits
35
The slide highlights a discrepancy in square footage to identify specific property assets (Potsdamer Straße 180, 182, and 184).Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory2 hits
10
Contains two distinct sections labeled as figures, detailing contractual instructions and data reliance.Vivion Investments · Carson Block
Research note Short seller Beat · AgitateLoop · Cost Of Inaction2 hits
13
This slide serves as a formal legal disclaimer regarding data provenance and verification limitations.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction2 hits
32
Includes a red box annotation highlighting 'Afeciano Limited' as a new entity in 2019.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction2 hits
36
This is a screenshot of a news article from The Marker, used as a source document.Vivion Investments · Carson Block
Research note Short seller Beat · SolutionLoop · Cost Of Inaction2 hits
03
Uses hyperbolic language ('gulags') and external citation (The Guardian) to frame the property negatively.Vivion Investments · Carson Block
Research note Short seller 2 hits
05
This is a text-heavy research note slide focusing on corporate governance and potential financial misconduct.Vivion Investments · Carson Block
Research note Short seller 2 hits
04
This is a research note from a short-seller report (MW = Muddy Waters). It uses a forensic accounting methodology to challenge company disclosures.Sunrun Inc. (RUN) · Carson Block
Research note Short seller Beat · Evidence & ProofLoop · Iceberg2 hits
02
Sunrun Inc. (RUN)Sunrun Inc. (RUN) · Muddy Waters Research
Activist deck Short seller Beat · Introduction2 hits